Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Peri-Procedural Myocardial Infarction, Platelet Reactivity, Thrombin Generation, and Clot Strength: Differential Effects of Eptifibatide + Bivalirudin Versus Bivalirudin -The CLEAR PLATELETS-2 Study

Next Previous
Trial Profile

Peri-Procedural Myocardial Infarction, Platelet Reactivity, Thrombin Generation, and Clot Strength: Differential Effects of Eptifibatide + Bivalirudin Versus Bivalirudin -The CLEAR PLATELETS-2 Study

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eptifibatide (Primary) ; Bivalirudin
  • Indications Coronary artery disease; Embolism and thrombosis
  • Focus Biomarker; Pharmacodynamics
  • Acronyms CLEAR-PLATELETS-2

Most Recent Events

  • 24 Feb 2009 Results published in Journal of the American College of Cardiology 53: 648-657, No. 8, 24 Feb 2009.
  • 06 Nov 2007 Status changed from recruiting to completed.
  • 06 Jul 2007 Interim results have been presented.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top